Invention Grant
- Patent Title: Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
-
Application No.: US14214728Application Date: 2014-03-15
-
Publication No.: US10221245B2Publication Date: 2019-03-05
- Inventor: Jennifer Brogdon , Carl H. June , Andreas Loew , Marcela Maus , John Scholler
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K14/725 ; C07K14/705 ; C07K16/28 ; C12N5/0783 ; A61K39/00
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
Public/Granted literature
- US20140271635A1 TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR Public/Granted day:2014-09-18
Information query
